<DOC>
	<DOCNO>NCT01026285</DOCNO>
	<brief_summary>International Observational Registry Schizophrenia</brief_summary>
	<brief_title>InORS - International Observational Registry Schizophrenia With Injectable Risperidone Oral Antipsychotics</brief_title>
	<detailed_description>This observational , non-interventional registry design assess medication usage pattern explore , clinical routine practice , long-term outcome relevant factor patient adherence treatment , patient receive antipsychotic treatment risperidone long-acting injectable ( RLAI ) oral antipsychotic . Six month retrospective data 1 year prospective data collect . According label</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<criteria>Patients must satisfy follow criterion eligible documentation noninterventional study : Diagnosis schizophrenia well 6 month retrospective clinical record Newly initiate switch RLAI oral antipsychotic treatment ( either atypical conventional ) , longer 2 week ago Signed inform consent ( either sign patient his/her legal representative ) available begin documentation schizophrenic patient ( include legal representative must sign consent ) involve study Established treatment refractory schizophrenia , define treatment failure adequate trial ( adequate judge treat physician ) 2 second generation ( atypical ) antipsychotic and/or clozapine History neuroleptic malignant syndrome</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Risperdal Consta</keyword>
</DOC>